X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
cc-486 (12) 12
index medicus (8) 8
oncology (8) 8
conventional care regimens (7) 7
myelodysplastic syndromes (6) 6
azacitidine (5) 5
hematology (5) 5
humans (5) 5
5-azacytidine (4) 4
acute myeloid leukemia (4) 4
cancer (4) 4
older patients (4) 4
oral azacitidine (4) 4
acute myelogenous leukemia (3) 3
care and treatment (3) 3
cc‐486 (3) 3
decitabine (3) 3
low-dose azacitidine (3) 3
maintenance therapy (3) 3
non-small cell lung cancer (3) 3
patients (3) 3
risk myelodysplastic syndromes (3) 3
safety (3) 3
stem-cell transplantation (3) 3
supportive care (3) 3
survival (3) 3
abridged index medicus (2) 2
administration, oral (2) 2
advanced (2) 2
aml (2) 2
analysis (2) 2
antimetabolites, antineoplastic - administration & dosage (2) 2
antimetabolites, antineoplastic - therapeutic use (2) 2
azacitidine - administration & dosage (2) 2
azacitidine - therapeutic use (2) 2
cc-486 oral azacitidine (2) 2
confidence intervals (2) 2
disease control (2) 2
dna methylation (2) 2
docetaxel (2) 2
epigenetic inheritance (2) 2
hemic and lymphatic diseases (2) 2
hypomethylating agent (2) 2
leukemia, myeloid, acute - drug therapy (2) 2
lung cancer (2) 2
mds (2) 2
medical research (2) 2
medicine, experimental (2) 2
middle aged (2) 2
myelodysplastic syndromes - drug therapy (2) 2
nanoparticle albumin-bound paclitaxel (2) 2
newly-diagnosed aml (2) 2
nivolumab (2) 2
non-small cell lung carcinoma (2) 2
nonsquamous (2) 2
open-label (2) 2
pembrolizumab (2) 2
pharmacokinetics (2) 2
quality-of-life (2) 2
randomization (2) 2
regulatory t-cells (2) 2
second-line (2) 2
stem cells (2) 2
thrombocytopenia (2) 2
toxicity (2) 2
treatment outcome (2) 2
1st-line therapy (1) 1
5-azacitidine (1) 1
5‐azacytidine (1) 1
abi-007 (1) 1
abnormalities (1) 1
acute myeloid-leukemia (1) 1
acute-leukemia (1) 1
adult (1) 1
adults (1) 1
age (1) 1
aged (1) 1
aged, 80 and over (1) 1
albumin (1) 1
allogeneic stem cell transplantation (1) 1
allogeneic transplantation (1) 1
anemia (1) 1
anemia; azacitidine; cc-486; ipss lower risk; mds; myelodysplastic syndromes; red blood cell transfusion dependence; thrombocytopenia (1) 1
anorexia (1) 1
anticancer agents (1) 1
anticancer properties (1) 1
antimetabolites, antineoplastic - blood (1) 1
antimetabolites, antineoplastic - chemistry (1) 1
antimetabolites, antineoplastic - pharmacokinetics (1) 1
antimitotic agents (1) 1
antineoplastic agents (1) 1
antineoplastic agents - chemistry (1) 1
antineoplastic agents - pharmacology (1) 1
antineoplastic agents - therapeutic use (1) 1
antineoplastic combined chemotherapy protocols - therapeutic use (1) 1
antitumor activity (1) 1
azacitidine - blood (1) 1
azacitidine - chemistry (1) 1
azacitidine - pharmacokinetics (1) 1
azacytidine (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European Journal of Cancer, ISSN 0959-8049, 12/2019, Volume 123, pp. 138 - 145
Treatment options are limited for recurrent nasopharyngeal carcinoma (NPC). We report results from a phase II study of CC-486 (oral azacitidine) in advanced... 
Nasopharyngeal carcinoma | Epigenetic | Pharmacokinetics | Azacitidine | CC-486
Journal Article
Journal Article
Cancer, 12/2018, Volume 124, Issue 24, p. 4667
This randomized phase 2 trial compared the efficacy and safety of second-line nanoparticle albumin-bound paclitaxel (nab-paclitaxel) with or without the... 
Journal Article
Journal Article
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.